Shanghai Shenqi Pharmaceutical Investment Management Second Quarter 2024 Earnings: EPS: CN¥0.029 (vs CN¥0.019 in 2Q 2023)

Simply Wall St · 09/01 01:07

Shanghai Shenqi Pharmaceutical Investment Management (SHSE:600613) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥535.8m (down 14% from 2Q 2023).
  • Net income: CN¥13.9m (up 27% from 2Q 2023).
  • Profit margin: 2.6% (up from 1.8% in 2Q 2023).
  • EPS: CN¥0.029 (up from CN¥0.019 in 2Q 2023).
earnings-and-revenue-history
SHSE:600613 Earnings and Revenue History September 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Shanghai Shenqi Pharmaceutical Investment Management shares are up 4.4% from a week ago.

Risk Analysis

Before you take the next step you should know about the 2 warning signs for Shanghai Shenqi Pharmaceutical Investment Management that we have uncovered.